<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052676</url>
  </required_header>
  <id_info>
    <org_study_id>STRAUSS-FRANSENOD</org_study_id>
    <secondary_id>CDR0000258612</secondary_id>
    <secondary_id>EU-20214</secondary_id>
    <nct_id>NCT00052676</nct_id>
  </id_info>
  <brief_title>Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer</brief_title>
  <official_title>French Randomized Sentinel Node Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Paul Strauss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: It is not yet known whether injecting technetium Tc 99m sulfur colloid and blue&#xD;
      dye near the tumor is more effective than injecting them near the nipple in identifying&#xD;
      sentinel lymph nodes in patients with stage I or stage II breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized diagnostic trial to compare the effectiveness of injecting technetium Tc&#xD;
      99m sulfur colloid and blue dye near the tumor with that of injections around the nipple in&#xD;
      detecting sentinel lymph nodes in patients who have stage I or stage II breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the optimal mode of injection (peritumoral vs periareolar) of patent blue V&#xD;
           dye and technetium Tc 99m sulfur colloid in patients with stage I or II breast cancer&#xD;
           undergoing sentinel lymph node identification.&#xD;
&#xD;
        -  Determine the reduction of morbidity associated with breast cancer surgery, in terms of&#xD;
           local control and survival, in patients undergoing sentinel lymph node identification&#xD;
           with these drugs.&#xD;
&#xD;
        -  Determine the evolution of disease in patients who have undergone this procedure and do&#xD;
           not show histological invasion of the sentinel lymph node.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive peritumoral injections of patent blue V dye and technetium Tc&#xD;
           99m sulfur colloid.&#xD;
&#xD;
        -  Arm II: Patients receive periareolar injections as in arm I. Patients in both arms&#xD;
           showing histological metastasis of the sentinel lymph node or without identification of&#xD;
           the sentinel lymph node undergo standard axillary lymph node dissection.&#xD;
&#xD;
      Patients are followed for disease evolution.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 450 patients (225 per arm) will be accrued for this study&#xD;
      within 2-2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patent blue V dye</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>technetium Tc 99m sulfur colloid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer&#xD;
&#xD;
               -  T0, T1, or T2 no greater than 3 cm, N0&#xD;
&#xD;
               -  Amenable to surgery&#xD;
&#xD;
          -  No inflammatory breast cancer&#xD;
&#xD;
          -  No ductal cancer in situ or multicentric invasive ductal cancer&#xD;
&#xD;
          -  No nipple/areola or central breast cancer (at least 2 cm from areola)&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No known allergy or intolerance to patent blue V dye&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior surgery for cancer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior neoadjuvant treatment for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Rodier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Paul Strauss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>F-33030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, Mignotte H, Br√©mond A, Classe JM, Dravet F, Routiot T, de Lara CT, Avril A, Lorimier G, Fondrinier E, Houvenaeghel G, Avigdor S. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007 Aug 20;25(24):3664-9. Epub 2007 May 7.</citation>
    <PMID>17485709</PMID>
  </results_reference>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

